Background Patients with psoriasis (PsO) are at increased risk of developing psoriatic arthritis (PsA). Emerging evidence ...

Background Cardiovascular disease and osteoarthritis (OA) share risk factors, but the link between comprehensive ...

Objectives Owing to the underrepresentation of early-stage disease in randomised trials and inconsistent clinical evidence, ...

Objectives To evaluate the long-term outcomes, clinical phenotypes and factors associated with complications in Still’s ...

Objective B-cell activating factor (BAFF) is essential for B-cell survival and innate immune activation, and its ...

Background Management of systemic lupus erythematosus (SLE) is largely guided by organ involvement. Serositis affects up to 46% of patients, yet its treatment is mainly empirical and extrapolated from ...

Objectives Nerandomilast, a selective phosphodiesterase 4B (PDE4B) inhibitor, has been extensively investigated for the treatment of pulmonary fibrosis; however, its therapeutic potential and ...

Objectives To identify glucocorticoid (GC) treatment patterns in patients with polymyalgia rheumatica (PMR) and explore patient profiles that may benefit from GC-sparing interventions. Methods This ...

Objectives This study aimed to determine the immunogenicity and the influence on disease activity of an adjuvanted recombinant varicella-zoster virus (VZV) subunit vaccine (RZV) in patients with ...

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterised by the presence of autoantibodies. Their value for diagnostic/prognostic purposes has been well established. In contrast, their ...

Background Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated 2-year efficacy in non-radiographic axial ...

Background Psoriatic arthritis (PsA) is a multifaceted condition with a broad spectrum of manifestations and a range of associated comorbidities. A notable segment of patients with PsA remains ...